Antibodies against monocyte chemotactic proteins

Abstract

The invention provides antibodies that bind to a plurality of β-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.

What is claimed is: 
     
         1 . A monoclonal antibody or antigen-binding fragment thereof comprising a heavy chain variable region having a CDR1 domain comprising the sequence set forth in SEQ ID NO:13, a CDR2 domain comprising the sequence set forth in SEQ ID NO:14, and a CDR3 domain comprising the sequence set forth in SEQ ID NO:15. 
     
     
         2 . The antibody or antigen binding fragment of  claim 1 , wherein the heavy chain variable region comprises the sequence set forth in SEQ ID NO:11. 
     
     
         3 . A monoclonal antibody or antigen-binding fragment thereof comprising a light chain variable region having a CDR1 domain comprising the sequence set forth in SEQ ID NO:16, a CDR2 domain comprising the sequence set forth in SEQ ID NO:17, and a CDR3 domain comprising the sequence set forth in SEQ ID NO:18. 
     
     
         4 . The antibody or antigen binding fragment of  claim 3 , wherein the light chain variable region comprises the sequence set forth in SEQ ID NO:12. 
     
     
         5 . The antibody or antigen binding fragment of  claim 1 , further comprising a light chain variable region having a CDR1 domain comprising the sequence set forth in SEQ ID NO:16, a CDR2 domain comprising the sequence set forth in SEQ ID NO:17, and a CDR3 domain comprising the sequence set forth in SEQ ID NO:18. 
     
     
         6 . The antibody or antigen binding fragment of  claim 2 , further comprising a light chain variable region comprising the sequence set forth in SEQ ID NO:12 
     
     
         7 . The antibody or antigen binding fragment of  claim 5 , wherein the antibody binds to MCP-1 and at least one other β-chemokine. 
     
     
         8 . The antibody or antigen binding fragment of  claim 7 , wherein the at least one other β-chemokine includes MCP-2. 
     
     
         9 . The antibody or antigen binding fragment of  claim 5 , wherein the antibody binds to MCP-1, MCP-2, and MCP-3. 
     
     
         10 . The antibody or antigen binding fragment of  claim 5 , wherein the antibody is a chimeric antibody. 
     
     
         11 . The antibody or antigen binding fragment of  claim 5 , wherein the antibody is a humanized antibody. 
     
     
         12 . The antigen binding fragment of  claim 5 , wherein the fragment is selected from a Fab fragment, a Fab′ fragment, a F(ab) 2  fragment, and a F v  fragment. 
     
     
         13 . A method of reducing chemotaxis in a subject suffering from a disorder selected from glomerulonephritis, scleroderma, cirrhosis, multiple sclerosis, lupus nephritis, atherosclerosis, inflammatory bowel disease or rheumatoid arthritis, comprising administering to the subject the antibody or antigen binding fragment thereof according to any one of  claims 1 - 12 . 
     
     
         14 . A method of reducing chemotaxis in a subject suffering from a disorder selected from glomerulonephritis, scleroderma, cirrhosis, multiple sclerosis, lupus nephritis, atherosclerosis, inflammatory bowel disease or rheumatoid arthritis, comprising administering to the subject the antibody or antigen binding fragment thereof comprising
 a) a heavy chain variable region having a CDR1 domain comprising the sequence set forth in SEQ ID NO:13, a CDR2 domain comprising the sequence set forth in SEQ ID NO:14, and a CDR3 domain comprising the sequence set forth in SEQ ID NO:15; and   b) a light chain variable region having a CDR1 domain comprising the sequence set forth in SEQ ID NO:16, a CDR2 domain comprising the sequence set forth in SEQ ID NO:17, and a CDR3 domain comprising the sequence set forth in SEQ ID NO:18.   
     
     
         15 . The method of  claim 14 , wherein the heavy variable region comprises the sequence set forth in SEQ ID NO:11, and the light chain variable region comprises the sequence set forth in SEQ ID NO:12.